A novel mitochondrial delivery method developed by Chinese researchers demonstrates significant therapeutic potential for Parkinson’s disease and Leigh syndrome in murine models. By encapsulating healthy mitochondria within red blood cell membranes, the team successfully enhanced mitochondrial uptake by recipient cells, achieving notable improvements in mitochondrial function and cell viability across various experimental conditions.

The encapsulated mitochondria showed superior stability and functionality compared to free-floating mitochondria, as evidenced by enhanced membrane potential and ATP production. In vitro experiments revealed that approximately 80% of recipient cells acquired donor mitochondria, leading to restoration of mitochondrial morphology and function. In vivo, the delivery method markedly improved survival rates in Leigh syndrome models and significantly rescued dopaminergic neurons in Parkinson’s models, reversing behavioral symptoms of bradykinesia. Importantly, these effects persisted for at least three months, indicating a long-lasting therapeutic impact.

This study shifts the paradigm in mitochondrial disease research by providing a feasible method for targeted mitochondrial therapy. The ability to deliver functional mitochondria efficiently opens new avenues for drug development and therapeutic strategies aimed at addressing mitochondrial dysfunction, a critical factor in aging and neurodegenerative diseases. The implications for clinical translation are profound, as this approach could lead to more effective treatments for patients suffering from mitochondrial disorders, potentially reducing the burden of these diseases in clinical settings.

Source: lifespan.io